Management Restructuring for Late-Stage Clinical and Commercialization

Vivace Therapeutics, a private biotech company, announced on August 26, 2026, the appointment of Craig Gibbs as President and CEO and Ellen Lubman as Chief Business and Strategy Officer. Tim Clackson also joined the board, strengthening the company’s capabilities in clinical development, business development, and M&A. This leadership change signals a strategic shift from early discovery to late-stage clinical operations, capital raising, partnership strategies, and commercialization, which are now critical to the company’s valuation.

VT3989 Aims for First Phase 3 Entry as a TEAD Inhibitor

VT3989 is an oral TEAD palmitoylation inhibitor in clinical development under a code name, without a proprietary or international non-proprietary name. It targets Hippo pathway-dependent tumors by inhibiting the YAP·TAZ·TEAD transcription complex. The ongoing Phase 1/2 trial NCT04665206 began in March 2021 and is evaluating monotherapy and combination therapy in treatment-refractory solid tumors and mesothelioma. The FDA has issued a go-ahead for the Phase 3 sTEADfast trial, and the company plans to initiate the first patient dosing in December 2026 for second- or third-line mesothelioma patients who have received prior immunotherapy and chemotherapy.

Early Efficacy is Promising, but Confirmation is Still Needed

An interim analysis published in Nature Medicine showed an objective response rate (ORR) of 26% among 47 mesothelioma patients who received the clinical optimal dose of VT3989. Among 22 patients whose dose and urine albumin-to-creatinine ratio were further optimized, the ORR was 32%, the disease control rate was 86%, and the median progression-free survival was 10 months. Major toxicities were mostly Grade 1 or 2 proteinuria, peripheral edema, and fatigue. However, as this was a small, non-randomized interim analysis, the survival benefit and safety profile must be confirmed in Phase 3 compared to standard-of-care therapies.

Regulatory Designations and Treatment Landscape Support Development Rationale

The FDA granted orphan drug designation on July 30, 2025, and on August 26, 2026, the company reaffirmed its fast-track designation and the go-ahead for sTEADfast. These are development and review support measures, not approvals or advisory committee votes, and VT3989 remains in Phase 1/2 trials with preparations for the registration Phase 3 trial. Current first-line standard-of-care includes Bristol Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) combination, Merck & Co.’s Keytruda (pembrolizumab) and pemetrexed plus platinum-based chemotherapy, and the Phase 3 control arm will be gemcitabine or vinorelbine.

Reduced Competition Strengthens Leadership Position

Ikena Oncology discontinued its Phase 1 trial of TEAD1 inhibitor IK-930 in May 2024, but Novartis AG’s YAP·TEAD binding inhibitor IAG933 remains in Phase 1 NCT04857372, which as of June 2026 is in the post-treatment follow-up phase (active, not recruiting). Therefore, while VT3989 is the most clinically advanced TEAD family candidate, it is not an exclusive asset with no competition. The global mesothelioma treatment market was estimated at USD 548.4 million in 2025, and the USD 35 million Series D led by RA Capital in March 2025 supports registration trial preparation, though additional capital or partnerships will be critical for full Phase 3 execution.